KLF17 and non-small cell lung carcinoma: It is demonstrated that KLF17 is frequently downexpressed in the majority of human cancers, including breast cancer, lung adenocarcinoma, hepatocellular carcinoma (HCC), gastric cancer, papillary thyroid carcinoma (PTC), and non-small cell lung cancer (NSCLC) [17–22].